Silence Therapeutics (OTCMKTS:SLNCF) Trading 10% Higher – Still a Buy?

Silence Therapeutics plc (OTCMKTS:SLNCFGet Free Report) shares rose 10% on Wednesday . The stock traded as high as $2.17 and last traded at $1.65. Approximately 2,822 shares were traded during trading, a decline of 80% from the average daily volume of 14,372 shares. The stock had previously closed at $1.50.

Silence Therapeutics Price Performance

The company’s 50-day moving average price is $1.20 and its 200 day moving average price is $1.45.

About Silence Therapeutics

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Featured Articles

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.